8 insiders reported 37 Form 4 transactions for ENANTA PHARMACEUTICALS INC (ENTA) over the past 18 months (most recent 2026-08-10). Recent activity: Rottinghaus Scott T. (Chief Medical Officer) Sell 1,467 shares, Kowalsky Matthew Paul (Chief Legal Officer) Buy 1,318 shares, Rottinghaus Scott T. (Chief Medical Officer) Buy 5,225 shares, Rottinghaus Scott T. (Chief Medical Officer) Sell 3,413 shares, Or Yat Sun (Chief Scientific Officer) Buy 1,650 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | Rottinghaus Scott T. | Chief Medical Officer | Sell | 1,467 | $19,570 |
| 2026-02-13 | Kowalsky Matthew Paul | Chief Legal Officer | Buy | 1,318 | $0 |
| 2026-02-13 | Rottinghaus Scott T. | Chief Medical Officer | Buy | 5,225 | $0 |
| 2026-02-13 | Rottinghaus Scott T. | Chief Medical Officer | Sell | 3,413 | $48,635 |
| 2026-02-13 | Or Yat Sun | Chief Scientific Officer | Buy | 1,650 | $0 |
| 2026-02-13 | Or Yat Sun | Chief Scientific Officer | Buy | 5,225 | $0 |
| 2026-02-13 | Or Yat Sun | Chief Scientific Officer | Sell | 3,413 | $48,635 |
| 2026-02-13 | Luly Jay R. | President and CEO | Buy | 4,800 | $0 |
| 2026-02-13 | Luly Jay R. | President and CEO | Buy | 15,200 | $0 |
| 2026-02-13 | Luly Jay R. | President and CEO | Sell | 6,155 | $87,709 |
| 2026-02-13 | Kieffer Tara Lynn | Chief Product Strategy Officer | Buy | 1,575 | $0 |
| 2026-02-13 | Kieffer Tara Lynn | Chief Product Strategy Officer | Buy | 4,987 | $0 |
| 2026-02-13 | Kieffer Tara Lynn | Chief Product Strategy Officer | Sell | 3,257 | $46,412 |
| 2026-02-13 | Rottinghaus Scott T. | Chief Medical Officer | Buy | 1,650 | $0 |
| 2026-02-13 | Kowalsky Matthew Paul | Chief Legal Officer | Buy | 4,175 | $0 |
| 2026-02-13 | Kowalsky Matthew Paul | Chief Legal Officer | Sell | 1,902 | $27,104 |
| 2026-02-13 | Luu Brendan | Chief Business Officer | Buy | 1,575 | $0 |
| 2026-02-13 | Luu Brendan | Chief Business Officer | Buy | 4,987 | $0 |
| 2026-02-13 | Luu Brendan | Chief Business Officer | Sell | 3,257 | $46,412 |
| 2025-12-05 | Or Yat Sun | Chief Scientific Officer | Sell | 2,390 | $34,010 |
| 2025-12-05 | Capps Kathleen S. | See Remarks | Sell | 323 | $4,596 |
| 2025-12-05 | Trout Harry R. III | See Remarks | Sell | 542 | $7,713 |
| 2025-12-05 | Kieffer Tara Lynn | Chief Product Strategy Officer | Sell | 2,106 | $29,968 |
| 2025-12-05 | Luu Brendan | Chief Business Officer | Sell | 1,394 | $19,837 |
| 2025-12-05 | Luly Jay R. | President and CEO | Sell | 4,743 | $67,493 |
Source: SEC Form 4 filings · as of 2026-08-10